Patents by Inventor Edward McDonald
Edward McDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7622692Abstract: Systems and methods for sorting a plurality of unaddressed items may comprise receiving delivery point address data. Furthermore, systems and methods for sorting a plurality of unaddressed items may comprise sorting the plurality of unaddressed items based on the delivery point address data. The plurality of unaddressed items may be sorted in an order in which they are to be delivered within a delivery zone specified by the delivery point address data.Type: GrantFiled: January 24, 2007Date of Patent: November 24, 2009Assignee: United States Postal ServiceInventors: Glenn Edward McDonald, Wilson Wong
-
Patent number: 7612201Abstract: Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers.Type: GrantFiled: December 18, 2003Date of Patent: November 3, 2009Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., The Institute of Cancer ResearchInventors: Mandy Christine Beswick, Martin James Drysdale, Brian William Dymock, Edward McDonald
-
Publication number: 20090270427Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: ApplicationFiled: April 30, 2009Publication date: October 29, 2009Applicants: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin FISHER, Michael JARMAN, Edward MCDONALD, Bernard NUTLEY, Florence RAYNAUD, Stuart WILSON, Paul WORKMAN
-
Publication number: 20090264490Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: ApplicationFiled: April 8, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic, Inc.Inventors: John Myers ZANELLA, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Publication number: 20090264491Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.Type: ApplicationFiled: April 9, 2009Publication date: October 22, 2009Applicants: WARSAW ORTHOPEDIC, INC., MEDTRONIC, INC.Inventors: William F. MCKAY, Amira WOHABREBBI, Vanja Margareta KING, Phillip Edward MCDONALD, Christopher M. HOBOT, Troy CARTER
-
Publication number: 20090264472Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.Type: ApplicationFiled: April 8, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic, Inc.Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher M. Hobot, Phillip Edward McDonald
-
Publication number: 20090247579Abstract: The present invention pertains to certain 2-[3H-thiazol-2-ylidinemethyl]pyridine compounds and analogs thereof, which, inter alia, inhibit cell proliferation, treat cancer, etc., and more specifically to compounds of the following formula, wherein RA1, RA2, RA3, RA4, RB1, RB2, RNA, RNB, and X? are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative conditions such as cancer, etc.Type: ApplicationFiled: February 21, 2007Publication date: October 1, 2009Inventors: Robert Brown, Jane Plumb, Gladys Wynne Aherne, Edward McDonald, Keith Jones, Stephen Hilton
-
Publication number: 20090247507Abstract: Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2—, —O—, —SO2NH—, —NHSO2—, NHC(?O)NH, —NH(C?S)NH—, Or —N(R4)—wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylenType: ApplicationFiled: December 21, 2006Publication date: October 1, 2009Applicant: THE INSTITUTE OF CANCER RESEARCHInventors: Vassilios Bavetsias, Edward McDonald, Spyridon Linardopoulos
-
Patent number: 7582642Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: GrantFiled: January 11, 2005Date of Patent: September 1, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090156601Abstract: The invention provides compounds which are pyrimidines of formula (I): wherein —XR3 is bonded at ring position 2 and —YR4 is bonded at ring position 5 or 6; R1 and R2 form, together with the N atom to which they are attached, a morphorine ring which is unsubstituted or substituted; X is a direct bond; R3 is selected from (i) a group of the following formula (1): wherein B is a phenyl ring which is unsubstituted or substituted and Z is selected from —OR, CH2OR and —NRS(O) mR, wherein each R is independently selected from H, C1-C6 alkyl, C3-C10 cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the group being unsubstituted or substituted, and m is 2; and (ii) an indazole group which is unsubstituted or substituted; and Y is selected from —O—(CH2)n—, —NH—(CH2)n, —NHC(O)—(CH2)n— and —C(O)NH—(CH2)n— wherein n is 0 or an integer of 1 to 3, and R4 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted and a group —NR5R6 wherein R5 and R6,Type: ApplicationFiled: October 10, 2006Publication date: June 18, 2009Inventors: Edward McDonald, Jonathan M. Large, Adrian J. Folkes, Stephen J. Shuttleworth, Nan Chi Wan
-
Patent number: 7544689Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: GrantFiled: September 28, 2005Date of Patent: June 9, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090081273Abstract: Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: Medtronic, Inc.Inventors: Phillip Edward McDonald, Christopher M. Hobot
-
Publication number: 20090054421Abstract: Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R1 is -(Alk1)p-(Z)r(Alk2)-Q wherein AIk1 and AIk2 are optionally substituted divalent C1C3 alkylene or C2-C3 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO2—, —C(?O)O—, —C(?O)NRA, —C(?S)NRA-, —SO2NRA—NRAC(?O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is optionally substituted aryl or heteroaryl; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C-6)alkyl, aryl or heteroaryl radical; and R4 is (i) a carboxylic ester, carboxamide or sulfonamide group, or (ii) a —CN group, or (iii) an optionally substituted C1-C6alkyl, aryl, heteroaryl, aryl(C1-C6alkyl)-, or heteroaryl(C1-C6alkyl)- group, or (iv) a group of formula —C(?O)R5 wherein R5 is hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroarylType: ApplicationFiled: January 23, 2006Publication date: February 26, 2009Applicants: Vernalis R & D Limited, Cancer Research Technology LTD, THE INSTITUTE OF CANCER RESEARCHInventors: Thomas Peter Matthews, Kwai Ming Cheung, Ian Collins, Edward McDonald, Paul Andrew Brough, Martin James Drysdale
-
Publication number: 20090042884Abstract: Pyrimidines of formula (I): wherein R1 to R4, X and Y are defined in the specification are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: October 11, 2006Publication date: February 12, 2009Inventors: Edward McDonald, Jonathan M. Large, Stephen J. Shuttleworth
-
Patent number: 7479495Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.Type: GrantFiled: June 2, 2005Date of Patent: January 20, 2009Assignees: Pharmacopeia, Inc., Bristol-Myers Squibb CompanyInventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
-
Patent number: 7247734Abstract: The present invention pertains to the use of certain 3,4-diarylpyazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxyl; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamide; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.Type: GrantFiled: December 19, 2002Date of Patent: July 24, 2007Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., Institute of Cancer Research of Royal Cancer HospitalInventors: Martin James Drysdale, Brian William Dymock, Xavier Barril-Alonso, Paul Workman, Laurence Harris Pearl, Chrisostomos Prodromou, Edward McDonald
-
Publication number: 20070054909Abstract: Compounds that selectively inhibit the binding of ligands to ?4?1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.Type: ApplicationFiled: November 8, 2006Publication date: March 8, 2007Applicants: Daiichi Pharmaceutical Co., Ltd., Pharmacopeia Drug Discovery, Inc.Inventors: John Baldwin, Edward McDonald, Kevin Moriarty, Christopher Sarko, Nobuo Machinaga, Atsushi Nakayama, Jun Chiba, Shin Iimura, Yoshiyuki Yoneda
-
Patent number: 7179819Abstract: Compounds that selectively inhibit the binding of ligands to ?4?1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.Type: GrantFiled: February 26, 2004Date of Patent: February 20, 2007Assignees: Daiichi Pharmaceutical Co., Ltd., Pharmacopeia Drug Discovery, Inc.Inventors: John J. Baldwin, Edward McDonald, Kevin Joseph Moriarty, Christopher Ronald Sarko, Nobuo Machinaga, Atsushi Nakayama, Jun Chiba, Iimura Shin, Yoshiyuki Yoneda
-
Publication number: 20060241106Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO2—, —C(?O)O—, —C(?O)NRA—, —C(?S)NRA—, —SO2NRA—, —NRAC(?O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); andType: ApplicationFiled: February 9, 2004Publication date: October 26, 2006Inventors: Martin Drysdale, Brian Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen James, Kwai Cheung, Thomas Matthews
-
Publication number: 20060235058Abstract: Compound of a compound of formula (1) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.Type: ApplicationFiled: June 24, 2004Publication date: October 19, 2006Applicants: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., The Institute of Cancer ResearchInventors: Kwai Cheung, Brian Dymock, Edward McDonald, Martin Drysdale